


Buscar no portal

 (https://correio.anvisa.gov.br/owa)[The \(perguntas-frequentes\)](#) | [Legislation \(legislacao\)](#) | [Contact \(contato\)](#) | [services \(servicos\)](#) | [Press \(area-de-imprensa\)](#)

MENU

 **RSS Feed** (http://portal.anvisa.gov.br/noticias/-/asset_publisher/FXrpx9qY7FbU/rss?p_p_cacheability=cacheLevelFull) Print

RECORD

Anvisa approves three new biological medicines

Products will be used in the treatment of an unusual type of cancer, signs and symptoms of menopause and asthma.

By: Ascom / Anvisa

Posted: 06/06/2018 16:09

Last Modified: 06/12/2018 16:14

Tweetar

 Compartilhar

The National Agency of Sanitary Surveillance (Anvisa) registered three new biological medicines for commercialization in the national market. The first is Bavencio (avelumab), a rare disease treatment product approved for single use (single use) in adult Merkel (MCC) carcinoma (cancer) patients, an uncommon type of cancer exhibits aggressive clinical features.

The second was Duavive, indicated for the treatment of signs and symptoms associated with the fall of estrogen (female hormone), a fact that causes discomfort to the woman, such as hot flashes. This product was approved for the treatment of vasomotor symptoms (nerves responsible for the contraction and relaxation of blood vessels) classified as moderate to severe and associated with menopause.

Duavive is an innovative combination of conjugated estrogens and bazedoxifene acetates. The latter acts by inhibiting the negative effects associated with the isolated use of the female hormone. It can be used after the menopause has occurred in women who still have a uterus and have recorded the last natural menstrual period for more than 12 months.

The third approved product was Fasentra (benralizumab), indicated as adjuvant (maintenance) maintenance treatment for severe asthma with eosinophilic phenotype in adult patients.

The new registrations were published by Anvisa in the Official Gazette (DOU) on June 4, 2018.

Want to know Anvisa news first hand? Follow us on Twitter [@anvisa_oficial](https://twitter.com/anvisa_oficial) (https://twitter.com/anvisa_oficial) and Facebook [@AnvisaOficial](https://www.facebook.com/AnvisaOficial) (<https://www.facebook.com/AnvisaOficial/>)

Did you find any information wrong or outdated? [click here](#)

medicines (<http://portal.anvisa.gov.br/noticias/>)

[p_p_id=101_INSTANCE_FXrpx9qY7FbU&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&p_p_col_id=column-2&p_p_col_count=1&p_r_p_564233524_tag=medicamentos](http://portal.anvisa.gov.br/noticias/?p_p_id=101_INSTANCE_FXrpx9qY7FbU&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&p_p_col_id=column-2&p_p_col_count=1&p_r_p_564233524_tag=medicamentos) new (<http://portal.anvisa.gov.br/noticias/>)

[p_p_id=101_INSTANCE_FXrpx9qY7FbU&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&p_p_col_id=column-](http://portal.anvisa.gov.br/noticias/?p_p_id=101_INSTANCE_FXrpx9qY7FbU&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&p_p_col_id=column-2)

2&p_p_col_count=1&p_r_p_564233524_tag=novo+registro) biological (http://portal.anvisa.gov.br/noticias?p_p_id=101_INSTANCE_FXrpx9qY7FbU&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&p_p_col_id=column-2&p_p_col_count=1&p_r_p_564233524_tag=medicamentos+biol%C3%B3gicos) regimen
(http://portal.anvisa.gov.br/noticias?p_p_id=101_INSTANCE_FXrpx9qY7FbU&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&p_p_col_id=column-2&p_p_col_count=1&p_r_p_564233524_tag=novo+registro)

Back to top!

 (<https://www.facebook.com/AnvisaOficial/>)

 (<http://www.youtube.com/user/anvisaoficial>)

 (<https://twitter.com/audiovisualanvisa>)

Barra GovBr (<http://www.acessoinformacao.gov.br/>) (<http://www.brasil.gov.br/>)